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the Ethics Commission of Fuwai Hospital.
Continuous variables are expressed as the mean ± SD or medians
and interquartile ranges. Comparisons of categorical variables among
groups were conducted using Chi-square tests. ANOVA was used for
the comparison of means from multiple groups. Kaplan–Meier survival
curves were compared using the log-rank test. Cox proportional hazard
modeling was used to examine the associations between independent
factors and survival with adjustments for potential confounders. The
analyses were conducted with SPSS and a P value b 0.05 was used toDilated cardiomyopathy (DCM) is a disease of the heart muscle that
is characterized by ventricular dilatation and impaired systolic function.
The 5-year survival after the diagnosis of DCM is 50%, and the prediction
of death in patientswith DCM is still challenging [1,2]. QRS prolongation
on the electrocardiogram (ECG) represents an intraventricular conduc-
tion delay. Recent studies have indicated that QRS prolongation was a
predictor of mortality and arrhythmias in heart failure and DCM [3–5].
Accordingly, the aim of this present study was to assess the association
between QRS prolongation and mortality in a large sample of DCM
patients.
An observational cohort study of 1317 DCM hospitalized patients
was conducted from November 2003 to September 2011 in Fuwai
Hospital. DCM was deﬁned as systolic dysfunction with left ventricle
(LV) dilation in the absence of an apparent secondary cause of cardio-
myopathy [6]. Of the 1317 enrolled patients, 23 patients with missed
electrocardiograph test results and 175 patients were excluded from
the study with patients who had various secondary cardiomyopathies.
Thus, the ﬁnal analysis included 1119 patients. The primary end point
of the studywas all-cause mortality, which was assessed for all patients
by medical records and medical follow-up calls. The mean follow-upand Fuwai Hospital, Chinese
ollege, Beijing 100037, China.
land Ltd. Open access under CC BY-NCperiod was 3.5 ± 2.3 years, and the study protocol was approved by
determine statistical signiﬁcance.
The cohort consisted of 1119 patients with DCM (age: 51.1 ±
14.7 years, male: 73.4%), 19.3% (n = 216) had QRS N 150 ms,
23.0% (n = 257) had QRS = 120–150 ms, and 57.7% (n = 646)
had QRS b 120 ms. Compared with the QRS b 120 ms patients, the QRS
N 150 ms patients were older and more with females, longer disease
duration, larger LV diameter, and lower LV ejection fraction (LVEF)
value; QRS = 120–150 ms patients had larger left atrium (LA) diam-
eter, and less usage of beta-blockers, angiotensin-converting
enzyme inhibitors and angiotensin receptor blockers (Table 1).
During the mean follow-up of 3.5 ± 2.3 years, 268 (23.9%) died. Of
those, the all-cause mortality rates were highest in the patients with
QRS N 150 ms (n = 72, 33.3%), intermediate in those with QRS =120–
150 ms (n = 85, 33.1%), and lowest in those with QRS b 120 ms (n =
111, 17.2%), showing a signiﬁcant difference in the all-cause morbidity
risk among the QRS duration groups (log-rank χ2 = 42.811, P b 0.001,
Fig. 1).
Univariate analysis indicated that age, history of atrial ﬁbrillation
(AF), NYHA functional classes, disease duration, systolic blood pressure,
diastolic blood pressure, LV, LA, right ventricle (RV) diameters, LVEF,
and QRS duration, were the predictors of all-cause mortality in DCM
patients. After adjustment for age, sex, history of diabetes mellitus and
AF, smoking and drinking status, disease duration, heart rate, blood
pressure, LVEF, LV and RV diameter, the Cox multivariate analysis
showed that the QRS duration, LA diameter and NYHA functional class
were the independent predictors of all-cause mortality.
QRS prolongation is well-known to occur in the general population,
increasing sharply with age [7]. QRS duration is also reported to corre-
late with cardiac size, LV dilatation, and systolic dysfunction [7,8] and
an increased QRS duration was a risk factor for arrhythmic deaths and
all-cause mortality in post-myocardial infarction patients [9,10]. Recent
studies have suggested that a prolonged QRS duration is a risk factor for-ND license. 
Table 1
Patient characteristics categorized by QRS prolongation patterns.
All patients (n = 1119) QRS N 150 ms (n = 216) QRS = 120–150 ms (n = 257) QRS b 120 ms (n = 646) P value
Age (years) 51.1 ± 14.7 55.7 ± 12.1 53.7 ± 14.0 48.5 ± 15.2 b0.001
Female sex, n (%) 298(26.6) 72 (33.3) 62(24.1) 164(25.4) 0.043
History
Disease duration (years) 2(0.5–6) 4(1–8) 4(1–8) 1.5(0.25–5) b0.001
Atrial ﬁbrillation, n (%) 157(14.0) 36(16.7) 55(21.4) 166(25.7) 0.019
Smoker, n (%) 517(46.2) 90(41.7) 124(48.2) 303(46.9) 0.309
Drinker, n (%) 363(32.4) 67(31.0) 80(31.1) 216(33.4) 0.707
NYHA class III and IV, n (%) 817(73.0) 161(74.5) 191(74.3) 465(72.0) 0.662
Admission vital signs
SBP (mm Hg) 113.0 ± 17.7 112.4 ± 16.3 113.4 ± 19.8 113.1 ± 17.3 0.795
DBP (mm Hg) 72.5 ± 12.6 71.5 ± 12.2 71.5 ± 12.1 73.2 ± 12.9 0.088
Heart rate, beats/min 80.9 ± 17.4 78.1 ± 15.3 78.5 ± 17.0 82.8 ± 18.1 b0.001
Laboratory values at admission
Glucose (mmol/L) 5.62 ± 1.85 5.66 ± 1.73 5.68 ± 2.04 5.59 ± 1.81 0.764
Creatinine (μmol/L) 92.8 ± 35.2 95.7 ± 32.8 92.8 ± 31.9 91.8 ± 37.2 0.263
BUN (μmol/L) 7.95 ± 3.97 8.32 ± 4.35 8.13 ± 4.17 7.76 ± 3.74 0.158
Pro-NT BNP (fmol/mL) 2010.3 ± 1567.5 2068.5 ± 1500.7 2105.3 ± 1722.6 1951.2 ± 1521.9 0.469
Electrocardiogram data
QRS duration (ms) 119.6 ± 30.8 171.1 ± 15.5 129.8 ± 10.6 98.3 ± 11.8 b0.001
QT (ms) 405.7 ± 54.2 443.3 ± 48.1 417.5 ± 47.3 388.3 ± 51.1 b0.001
PR (ms) 182.8 ± 32.9 189.7 ± 36.5 188.1 ± 37.5 177.9 ± 28.1 b0.001
Echocardiography data
LVd (mm) 68.0 ± 9.3 71.2 ± 11.4 70.6 ± 9.9 66.0 ± 7.6 b0.001
LVEF (mm) 31.9 ± 8.4 30.4 ± 8.0 31.3 ± 8.0 32.6 ± 8.7 0.002
RV (mm) 23.6 ± 5.4 22.7 ± 5.0 23.7 ± 6.1 23.9 ± 5.2 0.030
LA (mm) 43.9 ± 7.7 44.2 ± 8.1 45.3 ± 8.0 43.3 ± 7.5 0.004
Medicine at admission
Diuretics, n (%) 1059(94.6) 204(94.4) 239(93.0) 616(95.4) 0.361
ACEI/ARB, n (%) 951(85.0) 182(84.3) 203(79.0) 566(87.6) 0.004
Beta-blockers, n (%) 1017(90.9) 189(87.5) 223(86.8) 605(93.7.) 0.001
Digoxin, n (%) 903(80.7) 173(80.1) 199(77.4) 531(82.2) 0.254
Aspirin/anticoagulation n (%) 721(64.4) 129(59.7) 159(61.9) 433(67.0) 0.094
Spironolactone, n (%) 1019(91.1) 190(88.0) 228(88.7) 601(93.0) 0.025
1. Data are expressed as mean ± SD or median (interquartile range) or as percentages, P values from an ANOVA for all three groups.
2. Thirty-four patients lacked echocardiography data, 341 patients lacked NT-pro-BNP levels, 52 patients lacked fasting blood glucose levels, 46 patients lacked creatinine, BUN levels.
3. Abbreviations: NYHA, New York Heart Association; SBP, systolic blood pressure; DBP, diastolic blood pressure; BUN, blood urea nitrogen; NT-pro-BNP, N-terminal fragment pro-brain
natriuretic peptide; LV, left ventricle; LA, left atrium; LVEF, left ventricular ejection fraction; ACEI, angiotensin- converting enzyme inhibitor; ARB, angiotensin receptor blocker.
Fig. 1. Kaplan–Meier survival curves for patients with dilated cardiomyopathy: The
patients with QRS N 150 ms, QRS = 120–150 ms and QRS b 120 ms (log-rank χ2 =
42.811, P b 0.001).
e476 X. Li et al. / International Journal of Cardiology 172 (2014) e475–e477mortality in patients with heart failure and DCM [3–5]. In our study, the
patients with QRS ≥ 120 ms had a higher all-cause mortality rate than
those with QRS b 120 ms and that QRS duration was a strong predictor
of all-cause mortality in patients with DCM even after adjustment for
the classic risk factors. However, we did not ﬁnd a difference in the
all-cause mortality rate between patients with QRS N 150 ms and
patients with QRS = 120–150 ms. In conclusion, the prolongation of
the QRS duration at admission is a predictor of mortality in patients
with DCM.
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